Accelerating the Development of Genetic Medicines with AI

The advent of genetic medicines is enabling the development of therapies that can repair or replace a faulty genetic sequence underlying a disease. WhiteLab Genomics has developed an AI-based platform to enable target discovery and design of DNA and RNA therapies in silico and shorten development times. We spoke to David Del Bourgo, CEO of WhiteLab Genomics, about its AI-platform technology, the data it uses, and its role in a consortium to develop highly specific vectors for genetic medicines.

Episode metadata supplied by the publisher feed · Published Dec 7, 2023

Embed this episode

Attribution link and audio player

What this episode covers

David Del Bourgo, CEO of WhiteLab Genomics, discusses its AI-platform technology, the data it uses, and its role in a consortium to develop highly specific vectors for genetic medicines.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Accelerating the Development of Genetic Medicines with AI

0:00 19:15

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of RARECast?

This episode is 19 minutes long.

When was this RARECast episode published?

This episode was published on December 7, 2023.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!